165 related articles for article (PubMed ID: 15984518)
1. [Changes in tumor marker levels as a predictor of gemcitabine effect on patients with unresectable or recurrent pancreatic cancer].
Tendo M; Nakata B; Nishino H; Inoue M; Kosaka K; Amano R; Yamada N; Hirakawa K
Gan To Kagaku Ryoho; 2005 Jun; 32(6):795-8. PubMed ID: 15984518
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features of long time survivors with unresectable pancreatic cancer treated by gemcitabine alone].
Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Fujisawa N; Yoneda M; Abe Y; Inamori M; Kawamura H; Kirikoshi H; Shimamura T; Kubota K; Sakaguchi T; Saito S; Nakajima A
Gan To Kagaku Ryoho; 2006 Feb; 33(2):207-12. PubMed ID: 16484857
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Ikeda M; Okada S; Tokuuye K; Ueno H; Okusaka T
Br J Cancer; 2002 May; 86(10):1551-4. PubMed ID: 12085203
[TBL] [Abstract][Full Text] [Related]
4. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer.
Wang X; Ni Q; Jin M; Li Z; Wu Y; Zhao Y; Feng F
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):404-7. PubMed ID: 12408777
[TBL] [Abstract][Full Text] [Related]
6. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer.
Halm U; Schumann T; Schiefke I; Witzigmann H; Mössner J; Keim V
Br J Cancer; 2000 Mar; 82(5):1013-6. PubMed ID: 10737382
[TBL] [Abstract][Full Text] [Related]
7. [Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
Nakamori S; Tujie M; Takahashi Y; Maruhashi S; Miyamoto A; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Gan To Kagaku Ryoho; 2004 Jan; 31(1):51-4. PubMed ID: 14750321
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
9. Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients.
Matsumoto K; Miyake Y; Kato H; Kawamoto H; Imagawa A; Toyokawa T; Nakatsu M; Ando M; Hirohata M; Yamamoto K
Digestion; 2011; 84(3):230-5. PubMed ID: 21860243
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of gemcitabine in patients with advanced pancreatic cancer.
Carmichael J; Fink U; Russell RC; Spittle MF; Harris AL; Spiessi G; Blatter J
Br J Cancer; 1996 Jan; 73(1):101-5. PubMed ID: 8554969
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
Rocha Lima CM; Green MR; Rotche R; Miller WH; Jeffrey GM; Cisar LA; Morganti A; Orlando N; Gruia G; Miller LL
J Clin Oncol; 2004 Sep; 22(18):3776-83. PubMed ID: 15365074
[TBL] [Abstract][Full Text] [Related]
12. Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer.
Onoue M; Terada T; Okuda M; Fujimoto K; Doi R; Imamura M; Inui K
Int J Clin Oncol; 2004 Jun; 9(3):174-8. PubMed ID: 15221601
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
Ma G; Sun Y; Fu S
Int J Clin Exp Pathol; 2015; 8(10):13284-8. PubMed ID: 26722531
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
Rocha Lima CM; Savarese D; Bruckner H; Dudek A; Eckardt J; Hainsworth J; Yunus F; Lester E; Miller W; Saville W; Elfring GL; Locker PK; Compton LD; Miller LL; Green MR
J Clin Oncol; 2002 Mar; 20(5):1182-91. PubMed ID: 11870159
[TBL] [Abstract][Full Text] [Related]
15. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
Small W; Berlin J; Freedman GM; Lawrence T; Talamonti MS; Mulcahy MF; Chakravarthy AB; Konski AA; Zalupski MM; Philip PA; Kinsella TJ; Merchant NB; Hoffman JP; Benson AB; Nicol S; Xu RM; Gill JF; McGinn CJ
J Clin Oncol; 2008 Feb; 26(6):942-7. PubMed ID: 18281668
[TBL] [Abstract][Full Text] [Related]
16. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
17. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA
Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma.
Yamagishi Y; Higuchi H; Izumiya M; Sakai G; Iizuka H; Nakamura S; Adachi M; Hozawa S; Takaishi H; Hibi T
J Gastroenterol; 2010 Nov; 45(11):1146-54. PubMed ID: 20549255
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
Loehrer PJ; Feng Y; Cardenes H; Wagner L; Brell JM; Cella D; Flynn P; Ramanathan RK; Crane CH; Alberts SR; Benson AB
J Clin Oncol; 2011 Nov; 29(31):4105-12. PubMed ID: 21969502
[TBL] [Abstract][Full Text] [Related]
20. Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
Roehrig S; Wein A; Albrecht H; Konturek PC; Reulbach U; Männlein G; Wolff K; Ostermeier N; Hohenberger W; Hahn EG; Boxberger F
Med Sci Monit; 2010 Mar; 16(3):CR124-131. PubMed ID: 20190682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
